Revolution Medicines (RVMD) Share-based Compensation (2019 - 2026)

Revolution Medicines' Share-based Compensation history runs 8 years deep, the most recent figure standing at $87.3 million for Q1 2026.

• On a quarterly basis, Share-based Compensation rose 248.03% year-over-year to $87.3 million in Q1 2026; TTM through Mar 2026 was $151.6 million, a 671.05% increase from a year earlier, with the FY2025 full-year figure at $208.4 million, up 75.42% from the prior year.
• Share-based Compensation declined to $87.3 million in Q1 2026 per RVMD's latest filing, from $95.9 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $178.5 million in Q2 2025 and bottomed at -$56.8 million in Q4 2024.
• The 5-year median for Share-based Compensation is $13.7 million (2023), against an average of $46.4 million.
• Across the five-year window, Share-based Compensation sank 469.21% in 2022 and soared 814.48% in 2024, its largest moves.
• Year by year, Share-based Compensation stood at -$22.9 million in 2022, then surged by 51.6% to -$11.1 million in 2023, then plunged by 412.53% to -$56.8 million in 2024, then soared by 269.02% to $95.9 million in 2025, then retreated by 9.0% to $87.3 million in 2026.
• Per Business Quant, the three latest RVMD Share-based Compensation figures stand at $87.3 million (Q1 2026), $95.9 million (Q4 2025), and $177.7 million (Q3 2025).